Meningitis Vaccine: Know The Name, Protect Yourself

Meningitis is a serious, often life-threatening disease that affects millions of people worldwide. It is caused by the inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. The best way to prevent meningitis is to get vaccinated. There are several meningitis vaccines available, including MenACWY (Menveo and MenQuadfi) and MenB (Bexsero and Trumenba). These vaccines help protect against different serogroups of the bacteria that cause meningococcal disease, which can lead to meningitis and bloodstream infections. While the vaccines are safe and effective, they may cause mild side effects, such as redness and swelling at the injection site. It is important to consult a healthcare provider to determine the appropriate vaccine and understand its potential risks and benefits.

MenACWY vaccines (Menveo and MenQuadfi) protect against serogroups A, C, W, and Y

Meningitis is a serious and often life-threatening illness that affects millions of people worldwide each year. It is caused by the swelling of the meninges, the lining of the brain and spinal cord. Vaccines are available that provide protection against the most common causes of the disease and significantly reduce the chance of infection.

Meningococcal vaccines help protect against meningococcal disease, which can lead to bacterial meningitis and blood infections. There are six meningococcal vaccines available in the United States, which are grouped into three types: conjugate, polysaccharide, and recombinant. These vaccines help the body fight off meningococcal disease by introducing a harmless form of the bacteria or virus, allowing the immune system to recognize and create protective antibodies.

MenACWY vaccines, including Menveo and MenQuadfi, are two of the available meningococcal vaccines. These vaccines help protect against four serogroups of the bacteria that cause meningococcal disease: A, C, W, and Y. They are approved for use in individuals two years of age and older and are known as quadrivalent meningococcal vaccines.

Menveo and MenQuadfi are both indicated for active immunization against invasive meningococcal disease caused by specific serogroups of Neisseria meningitidis. While they provide protection against serogroups A, C, W, and Y, they do not prevent serogroup B disease. It is important to note that these vaccines can cause mild side effects, such as swelling, redness, and pain at the injection site, headache, muscle aches, fever, or tiredness.

Overall, MenACWY vaccines, including Menveo and MenQuadfi, play a crucial role in protecting individuals from meningococcal disease caused by serogroups A, C, W, and Y. However, it is always recommended to consult with a healthcare provider to determine the most appropriate vaccine for an individual's needs.

MenB vaccines (Bexsero and Trumenba) protect against serogroup B

Meningitis is a serious, often life-threatening illness that affects millions of people worldwide. It is caused by the inflammation of the meninges, the lining of the brain and spinal cord. Vaccines are available to protect against the most common causes of the disease and significantly reduce the chance of infection.

Meningococcal vaccines, for example, help protect against meningococcal disease, which can lead to bacterial meningitis. There are several types of meningococcal vaccines available, each protecting against different serogroups of the bacteria that cause meningococcal disease. MenB vaccines, in particular, Bexsero and Trumenba, help protect against serogroup B meningococcal disease. These vaccines are not interchangeable, meaning the same vaccine product must be used for all doses. They are composed of proteins found on the surface of the bacteria and are approved based on their ability to demonstrate an immune response.

Bexsero is a suspension composed of four distinct antigens, including factor H binding protein (fHbp), Neisserial adhesin A (NadA), Neisserial heparin-binding antigen (NHBA), and PorA P1.4 immunodominant antigen of OMV NZ (strain NZ98/254). Trumenba, on the other hand, is a suspension composed of two recombinant lipidated factor H binding protein (fHbp) variants from N meningitidis serogroup B, one from subfamily A and one from subfamily B.

Both Bexsero and Trumenba are routinely administered as a 2-dose series, with doses given at least 6 months apart. For those at increased risk of meningococcal disease, such as people with certain complement deficiencies or those receiving treatment that inhibits terminal complement activation, three doses of either vaccine may be recommended. It is important to note that data on the effectiveness of interchanging meningococcal group B vaccines within a series is limited.

MenABCWY vaccines (Penbraya and Penmenvy) protect against serogroups A, B, C, W, and Y

Meningitis is a serious and often life-threatening illness that affects millions of people worldwide each year. It is caused by the swelling of the lining of the brain and spinal cord, known as the meninges. This swelling can lead to bacterial meningitis and blood infections, which can be deadly if left untreated.

To combat this deadly disease, several vaccines have been developed to provide protection against the most common causes of meningitis. One such vaccine is the MenABCWY vaccine, which includes two variations: Penbraya and Penmenvy. These vaccines offer protection against five serogroups of bacteria that cause meningococcal disease: A, B, C, W, and Y.

Penbraya, licensed in 2023, is recommended for healthy adolescents aged 16 and above. It is a 5-in-1 vaccine, meaning that one less injection is needed compared to separate MenACWY and MenB vaccines. This vaccine has been shown to produce an immune response, indicating that it provides protection. However, data on its effectiveness is limited.

Penmenvy, on the other hand, is the second pentavalent meningococcal vaccine to become available in the US. It is FDA-licensed for individuals aged 10 to 25 years old. Penmenvy contains the antigenic components of Menveo, a quadrivalent MenACWY vaccine, and Bexsero, a MenB vaccine. While the efficacy of Penmenvy is similar to that of separate MenACWY vaccines, it is similar or slightly inferior against MenB serogroup.

Both Penbraya and Penmenvy are important tools in the fight against meningitis, providing protection against five of the most common serogroups of bacteria that cause this deadly disease.

Meningococcal vaccines are safe and proven to help fight meningococcal disease

Meningococcal disease is a serious and potentially deadly illness that affects millions of people worldwide every year. It is caused by bacteria and can lead to bacterial meningitis (swelling around the brain and spinal cord) and blood infections. The disease is highly contagious and can spread through close contact and the exchange of respiratory and throat secretions.

Meningococcal vaccines are safe and have been proven to help fight meningococcal disease. These vaccines contain inactivated or killed bacteria, which means they cannot cause the disease they are designed to prevent. When an individual is vaccinated, their body's immune system produces antibodies that can recognise and destroy the bacteria, providing long-lasting protection. Vaccination not only protects the individual but also helps prevent the spread of the disease to others, including those who are too young to be vaccinated or have serious illnesses.

There are several types of meningococcal vaccines available, including MenACWY (such as Menveo® and MenQuadfi®), MenB (such as Bexsero® and Trumenba®), and MenABCWY (such as Penbraya™ and Penmenvy). These vaccines protect against different serogroups or strains of the bacteria that cause meningococcal disease. While these vaccines are effective, they may not prevent all cases, and protection may decrease over time, making booster shots necessary.

Meningococcal vaccines are generally safe, but mild side effects such as redness, swelling, and pain at the injection site may occur. More serious reactions, such as allergic reactions, are possible but rare. Vaccination is recommended for preteens and teens and individuals at increased risk of contracting the disease. It is important to consult a healthcare provider to determine the appropriate vaccination schedule and discuss any concerns or questions.

Overall, meningococcal vaccines are a safe and proven way to fight meningococcal disease. They help protect individuals and communities from this serious and potentially deadly illness.

Meningitis vaccines work by introducing a harmless form of the bacteria/virus into the body

Meningitis is a serious and often life-threatening condition that affects millions of people worldwide each year. It is caused by the inflammation of the protective membranes around the brain and spinal cord, known as the meninges. This inflammation can be triggered by various bacteria and viruses, leading to different types of meningitis, including bacterial, viral, fungal, parasitic, and amebic forms.

Bacterial meningitis, specifically meningococcal disease caused by the meningococcus bacteria, is considered one of the most severe types. It is highly contagious and can rapidly turn deadly if left untreated. To combat this threat, several vaccines have been developed to provide protection against specific strains of the bacteria that cause meningococcal disease.

Meningitis vaccines work by introducing a harmless form of the bacteria or virus into the body. This harmless form is known as an antigen. Once inside the body, the immune system recognizes the antigen as foreign and mounts a response by producing protective antibodies. These antibodies circulate in the bloodstream, ready to identify and destroy the actual bacteria or virus if exposure occurs in the future. This process of generating antibodies through vaccination helps the body develop immunity to the disease.

There are several types of meningococcal vaccines available, each targeting different serogroups (strains) of the bacteria. In the United States, there are currently three commonly used vaccines: MenACWY (protecting against serogroups A, C, W, and Y), MenB (protecting against serogroup B), and MenABCWY (protecting against serogroups A, B, C, W, and Y). The CDC recommends different vaccines for different age groups and risk factors. For example, the MenB vaccine is suggested for people aged 16-23, especially those at high risk, while the MenACWY vaccine is part of the routine childhood immunization schedule.

While these vaccines have proven effective in preventing meningococcal disease, it is important to note that they don't provide protection against all forms of the disease. Additionally, the protection offered by the vaccines wanes over time, emphasizing the importance of booster shots, particularly for teens who are at higher risk. Mild side effects may occur after vaccination, including redness, swelling, and pain at the injection site, but these typically resolve within a few days.

Frequently asked questions